Comparing the current results to its competitors, Geron reported Revenue increase in the 1 quarter 2026 by 30.89 % year on year. The sales growth was above Geron's competitors' average revenue growth of 7.52 %, achieved in the same quarter.
The competitive landscape involves the use of enforceable patents and contractual arrangements to protect business interests. Success depends in part on intellectual property strategy, including early technology development and focused innovation around product candidates such as RYTELO (imetelstat).
April 21, 2025
On May 12, 2025, the deadline will arrive for investors in Geron Corporation (NASDAQ: GERN) to join a class action lawsuit against the biotechnology firm. As the company navigates complex market conditions, shareholders must be informed of their rights and the potential implications of this legal action.Geron Corporation (NASDAQ: GERN), a biotechnology company focused on the development of novel therapies for hematologic malignancies and solid tumors, has drawn the attention of investors as it faces significant legal challenges. Currently, the company has approximately 646.56 million shares outstanding, and the stock is trading at $1.25 per share. This article aims to dissect the circumstances surrounding t...
April 12, 2025
In a significant development for investors in Geron Corporation (NASDAQ: GERN), a class action lawsuit has been filed against the company and certain officers, raising critical questions regarding corporate governance, accountability, and investor rights. The lawsuit, initiated by the Pomerantz Law Firm, is a response to alleged violations of federal securities laws, specifically targeting those who purchased or acquired Geron s securities during the designated Class Period from February 28, 2024, to February 25, 2025.The class action has been lodged in the United States District Court for the Northern District of California, under case number 25cv02563. The essence of the lawsuit focuses on claims under Sec...
April 7, 2025
In a significant legal development, Pomerantz LLP has announced the filing of a class action lawsuit against Geron Corporation (NASDAQ: GERN) and certain company officers. This lawsuit was initiated in the United States District Court for the Northern District of California, under docket number 25-cv-02563, and represents a class action on behalf of all individuals and entities that purchased or acquired Geron securities during the period from February 28, 2024, to February 25, 2025. The lawsuit seeks to recover damages attributed to alleged violations of federal securities laws and aims to enforce remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5 introduce...
March 28, 2025
In recent months, investors in Geron Corporation (NASDAQ: GERN) have found themselves at a critical juncture as the company faces a securities class action lawsuit. The Rosen Law Firm, known for its commitment to protecting investor rights, has issued advisories regarding the urgent need for affected shareholders to secure legal counsel. The announcements made on March 18 and March 28, 2025, emphasize the importance of complying with court deadlines and understanding the broader implications of the lawsuit. This article aims to elucidate the key details of the class action, the potential ramifications for shareholders, and the significance of legal guidance during this challenging period. Overview of the Cla...
March 27, 2025
This article examines the financial status of Geron Corporation with an emphasis on their current class action lawsuit and leverage ratios. It assesses the implications of rising debts and class action litigation, offering insights into the investment landscape for stakeholders. Geron Corporation, a biopharmaceutical firm focused on innovative cancer therapies, recently found itself at the center of investor scrutiny as Levi and Korsinsky LLP announced a pending class action securities lawsuit. Investors now have until May 12, 2025, to participate as lead plaintiffs. Amidst these legal challenges, an evaluation of Geron’s financial stability, as reflected in its leverage ratios, reveals a concerning tr...
August 8, 2024
As the landscape of blood cancer treatment continues to evolve, Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company based in Foster City, California, is making significant strides with its latest offerings. In its second quarter financial report for 2024, Geron has highlighted the promising launch of RYTELO (imetelstat), its first commercial product, which commenced in June. John, the company’s lead executive, expressed optimism regarding the initial uptake of RYTELO, stating, We are thrilled to have begun the launch of RYTELO and are encouraged by the early success we are seeing and the reception from the medical community over these first six weeks. This sentiment is indicative...
July 29, 2024
Geron Corporation’s Game-Changer: NCCN Endorsement for RYTELO In a significant development for the biopharmaceutical sector, Geron Corporation (Nasdaq: GERN) has secured an updated endorsement from the National Comprehensive Cancer Network (NCCN), resulting in RYTELO (imetelstat) being categorized as a recommended treatment for symptomatic anemia in patients with lower-risk Myelodysplastic Syndromes (MDS). This announcement marks a pivotal moment for Geron, as they aim to transform the landscape of blood cancer treatment. Understanding the Updates to NCCN GuidelinesThe NCCN, a prominent nonprofit alliance of leading cancer centers, is well-regarded for establishing practices that are heavily relied upon by...
July 26, 2024
: Geron Corporation s RYTELO (imetelstat) has received updated recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Oncology concerning its use in treating symptomatic anemia in patients with lower-risk Myelodysplastic Syndromes (MDS). This article examines the implications of these guidelines for clinical practice and patient care. Myelodysplastic Syndromes (MDS) encompass a diverse group of hematological disorders characterized by ineffective hematopoiesis leading to variable degrees of cytopenia. Patients with lower-risk MDS frequently experience complications such as symptomatic anemia, which significantly impacts quality of life and necessitates effecti...
June 7, 2024
In a significant development for patients with myelodysplastic syndromes (MDS), Geron Corporation has announced the FDA approval of RYTELO (imetelstat). This groundbreaking telomerase inhibitor has been approved for the treatment of adult patients with low- to intermediate-1 risk MDS and transfusion-dependent (TD) anemia. Patients eligible for this treatment are those who have not responded to four or more red blood cell units over eight weeks.Geron s Mission: Changing Lives by Changing the Course of Blood CancerGeron Corporation, a biopharmaceutical company based in Foster City, California, is dedicated to revolutionizing the treatment landscape for blood cancer patients. With the approval of RYTELO, Geron ...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Geron Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Geron Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
